Dyax Corp is a biopharmaceutical company focused on Hereditary Angioedema (HAE) and other Plasma-Kallikrein-Mediated (PKM) Disorders, and licensing and funded research portfolio. Dyax develops and commercializes treatments for hereditary angioedema. Dyax discovered and developed KALBITOR, a plasma kallikrein inhibitor, and is selling it in the United States for the treatment of acute attacks of HAE. Additionally, they discovered and are developing DX-2930, a human monoclonal antibody inhibitor of plasma kallikrein. They also developed a biomarker assay that detects the activation of plasma kallikrein in patient blood. Dyax has a portfolio of product candidates being developed by licensees using its phage display technology. This portfolio includes one approved product, CYRAMZA (ramucirumab), which is marketed by Eli Lilly and Company (Lilly), and multiple product candidates in various stages of clinical development.

Dyax Corp has been purchased by Shire.